Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity ... Novo Nordisk and Eli Lilly and potential ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...

Shares in Eli Lilly rose sharply in pre-market trading today after the company ... an oral alternative to current injectable drugs for obesity. The results from the ACHIEVE-1 study – one of ...

I believe orforglipron’s approval should finally lead to widespread and global availability of obesity medicines ... improve Eli Lilly’s leadership position in this market and these results ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap ... on new branded obesity scripts ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...